FOLH1 and prostate carcinoma: First, it expresses multiple tumor-associated antigens: e.g., prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), and prostate stem cell antigen (PSCA), which provide a reliable therapeutic target for prostate cancer immunotherapy (18–20).